CONFERENCE DAY TWO
8:00 am Check-In & Light Breakfast
8:50 am Chair’s Opening Remarks
Enhancing Patient Response Rate to Combination Therapies by Targeting the Tumor Microenvironment
9:00 am Enhancing T Cell Capacity & Sensitizing Tumors for T Cell Killing by TME Gene Engineering to Enhance ICI & TIL Therapy
Synopsis
• How TME gene engineering can activate, stimulate and attract T and NK cells to the TME though chemokine release and transmigration from blood vessels, invoking antitumor immunity, and enhancing tumor cell immunogenicity
• How TME gene engineered vectors can be administered with ICIs to treat solid tumors, supported by clinical data
• How TME gene engineered vectors can be combined with adoptive T cell therapy can enhance patient response, supported by preclinical data
9:30 am Employing Advanced Analytics & AI to Design Next-Generation Viral Immunotherapy Combinations to Stimulate an Immune Response at the Tumor Microenvironment
Synopsis
• How AI data platforms can unpick tumor heterogeneity and analyze patient data toinform viral immunotherapy combination strategies for precise tumor targeting
• How data discovery platforms can identify pathways associated with therapeutic response to inform design of efficacious combination strategies of OV with ICIs and cell therapies
• How local delivery of viral immunotherapy can limit systemic toxicity and modify the tumor microenvironment, allowing improved therapeutic action of ICIs
10:00 am Targeting the Immunosuppressive Tumor Microenvironment through Combining the TVAX Vaccination & Adoptive Cell Therapy Platform with OV
Synopsis
• How the TVAX immunotherapy platform employs multiple modalities, including vaccination and autologous adoptive T cell therapy to target recurrent glioblastoma
• How to address challenges in targeting the tumor microenvironment, demonstrated through clinical data from patients with newly diagnosed glioblastoma receiving the TVIBrain-1
• How to overcome tumor microenvironment immunosuppression through the combination of TVAX immunotherapy with oncolytic virotherapy
10:30 am Morning Networking Break
Navigating Patient Selection, Dosing & Regulatory Considerations to Ensure Clinical Success for Novel Combination Cancer Immunotherapies
11:00 am Using Complementary Preclinical Models to Increase Success in Biomarker Discovery for ADC ICI Combinations
Synopsis
• How smart preclinical models are overcoming limitations in modelling the human immune system and tumor microenvironment
• How In vitro, ex vivo and in vivo models can provide complementary data to inform biomarker discovery and indicate patient response to ADC combination therapies.
• How tumor explant, tumor spheroid and humanized mouse models can be compared and contrasted to identify common PD and efficacy biomarkers
11:30 am Roundtable Discussion: Is Regulation Advancing as Rapidly as the Combination Cancer Immunotherapy Landscape? Evolving Regulation for the Clinical Complexities of Combining Multiple Novel Therapies for Cancer Patients
Synopsis
• Applying ‘Project Optimus’ to combination immunotherapy: clever consideration of dose optimization for improved patient outcome
• How to determine appropriate clinical end points for immunotherapy trials to indicate drug efficacy and durability?
12:30 pm Clinical update on DK210 (EGFR): Reducing Toxicity & Enhancing Potency of Cytokine Therapy through Rational Combination Strategies
Synopsis
• Coupling IL-10 with IL-2 reduces IL-2 toxicity by attenuating the induction of cytokine release syndrome
• Coupling IL-10 with IL-2 uncouples toxicity from T and NK cell activation, reducing risk of vascular/capillary leak syndrome
• Targeting to the surface of tumor cells enhances anti-tumor potency in vivo through its independent accumulation in the T cell synapse, enhancing T cell recognition and cytolytic function
1:00 pm Lunch & Networking Break
Achieving Better Translatability from Preclinical to Clinical Development with Smart Models, Resistance Investigation & Addressing Toxicity
2:00 pm Novel Combination Using Next Generation HSV-1 Oncolytic Immunotherapy
Synopsis
• Development of the next generation oncolytic HSV-1 immunotherapy
• RP1 combined with nivolumab overcomes resistance in PD-1 failed melanoma
• RP1 monotherapy is safe and effective in solid organ transplant recipients
2:30 pm Validation & Screening with a Novel Antigen-Specific, HCI Assay of Primary CD8 T Cell Killing of Tumor Cell Spheroids
3:00 pm Integrating Oncolytic Virotherapy into Immunotherapy Combinations to Overcome Resistance to Immune Checkpoint Inhibitors
Synopsis
- ICIs have been integrated into many tumor types and have become the backbone of many cancer treatments
- Response to ICI is limited due to ‘cold tumors’ and development of resistance
- Oncolytic viruses are able to change the tumour microenvironment and may provide a solution for patients who are ICI-refractory
3:30 pm Anchored Immunotherapy as a Strategy for Targeting Cytokine Retention in the Tumor Microenvironment to Promote Tumor Regression Without Systemic Toxicity
Synopsis
• How Anchored immunotherapy is a novel drug delivery strategy that promotes local cytokine retention of and limits systemic diffusion
• How Anchored immunotherapy can increase the therapeutic window for immunooncology agents such as IL-12, to promote local effector anti-tumor T cell responses
• Combination therapy with anchored drugs can further drive therapeutic responses without adding systemic toxicity with immune checkpoint blockade, chemotherapy, and radiation therapy